We are live on ! Find out more
CELZ icon

Creative Medical Technology
CELZ

8 hedge funds and large institutions have $104K invested in Creative Medical Technology in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

8% more capital invested

Capital invested by funds: $96.2K → $104K (+$8.17K)

0.01% more ownership

Funds ownership: 1.47% → 1.48% (+0.01%)

11% less funds holding

Funds holding: 9 → 8 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
8
Holders Change
-1
Holders Change %
-11.11%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$5.48K
2
Wells Fargo
Wells Fargo
California
+$102
3
Osaic Holdings
Osaic Holdings
Arizona
+$5

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$3.21K
2
IA
IFP Advisors
Florida
-$255
3
ODG
O'Dell Group
Ohio
-$5

CELZ Hedge Fund Activity: Q3 2023 in Review

8 of the 6,309 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q3 2023, worth a combined $104K — up 8.5% from $96.2K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CELZ and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was UBS Group, adding an estimated $5.48K. The largest seller was Tower Research Capital (TRC), cutting an estimated $3.21K.

  • 8 institutional investors held Creative Medical Technology (CELZ) as of Q3 2023, down from 9 in Q2 2023.
  • Funds reported $104K of Creative Medical Technology stock for Q3 2023, up 8.5% quarter-over-quarter.
  • 0 funds opened new Creative Medical Technology positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest Creative Medical Technology buyer in Q3 2023 was UBS Group, an estimated $5.48K added.
  • The largest Creative Medical Technology seller in Q3 2023 was Tower Research Capital (TRC), an estimated $3.21K sold.

Based on aggregated 13F filings for Q3 2023.